ci 994 has been researched along with Glioblastoma in 1 studies
tacedinaline: oral cytostatic drug with impressive differential activity against leukemic cells & normal stem-cells
tacedinaline : A benzamide obtained by formal condensation of the carboxy group of 4-acetamidobenzoic acid with one of the amino groups of 1,2-phenylenediamine. An oral cytostatic drug with impressive differential activity against leukemic cells and normal stem-cells. Also used in combination therapy for selected tumors including non-smoll cell lung, pancreatic, breast, and colorectal cancers.
Glioblastoma: A malignant form of astrocytoma histologically characterized by pleomorphism of cells, nuclear atypia, microhemorrhage, and necrosis. They may arise in any region of the central nervous system, with a predilection for the cerebral hemispheres, basal ganglia, and commissural pathways. Clinical presentation most frequently occurs in the fifth or sixth decade of life with focal neurologic signs or seizures.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Marquardt, V | 1 |
| Theruvath, J | 1 |
| Pauck, D | 1 |
| Picard, D | 1 |
| Qin, N | 1 |
| Blümel, L | 1 |
| Maue, M | 1 |
| Bartl, J | 1 |
| Ahmadov, U | 1 |
| Langini, M | 1 |
| Meyer, FD | 1 |
| Cole, A | 1 |
| Cruz-Cruz, J | 1 |
| Graef, CM | 1 |
| Wölfl, M | 1 |
| Milde, T | 1 |
| Witt, O | 1 |
| Erdreich-Epstein, A | 1 |
| Leprivier, G | 1 |
| Kahlert, U | 1 |
| Stefanski, A | 1 |
| Stühler, K | 1 |
| Keir, ST | 1 |
| Bigner, DD | 1 |
| Hauer, J | 1 |
| Beez, T | 1 |
| Knobbe-Thomsen, CB | 1 |
| Fischer, U | 1 |
| Felsberg, J | 1 |
| Hansen, FK | 1 |
| Vibhakar, R | 1 |
| Venkatraman, S | 1 |
| Cheshier, SH | 1 |
| Reifenberger, G | 1 |
| Borkhardt, A | 1 |
| Kurz, T | 1 |
| Remke, M | 1 |
| Mitra, S | 1 |
1 other study available for ci 994 and Glioblastoma
| Article | Year |
|---|---|
Tacedinaline (CI-994), a class I HDAC inhibitor, targets intrinsic tumor growth and leptomeningeal dissemination in MYC-driven medulloblastoma while making them susceptible to anti-CD47-induced macrophage phagocytosis via NF-kB-TGM2 driven tumor inflammat
Topics: Animals; Cerebellar Neoplasms; Glioblastoma; Histone Deacetylase Inhibitors; Humans; Inflammation; M | 2023 |